Every year, FDA publishes a document that receives far less attention than it deserves: the Human Foods Program Guidance Agenda.
It is not a new regulation. It does not create new legal requirements. And it does not immediately change anyone’s compliance obligations.
What it does provide is something many companies find even more valuable: a preview of where FDA intends to focus its policy development efforts and regulatory attention in the months ahead. Guidance documents often become the framework FDA investigators, reviewers, and compliance officials use when assessing whether companies are meeting the Agency’s expectations. As a result, FDA’s guidance agenda can offer an early glimpse into future enforcement priorities and emerging compliance risks.
The recently released 2026 Human Foods Program Guidance Agenda suggests that FDA’s attention is increasingly focused on transparency, labeling, food chemical safety, nutrition policy, and modernizing how companies communicate information to consumers.
Labeling and Claims Are Moving to the Forefront
One of the most notable aspects of the 2026 agenda is FDA’s planned work on several guidance documents that directly affect how products are marketed and labeled.
Among the new guidance topics FDA identified are:
- Labeling caffeine content in foods and beverages
- Questions and answers regarding use of the “Healthy” claim
- Food facility registration product categories and classification practices
These subjects may sound technical, but they have significant implications for food, beverage, dietary supplement, and functional food companies.
Caffeine Disclosure
FDA plans to develop draft guidance addressing caffeine-content labeling in foods and beverages. While the Agency has not yet released proposed language, the topic reflects growing regulatory interest in consumer understanding of caffeine exposure, particularly in energy drinks, powders, functional beverages, shots, and other products that blur traditional product categories.
For companies marketing caffeinated products, this could eventually affect:
- Nutrition Facts disclosures;
- Front-of-package statements;
- Voluntary caffeine declarations; and
- Marketing messages emphasizing energy, focus, or performance benefits.
The “Healthy” Claim
FDA also intends to issue guidance in a question-and-answer format regarding use of the “healthy” claim. While FDA has already been working to modernize the definition of “healthy,” additional guidance could provide more clarity regarding claim substantiation and application across product categories.
Companies that currently use nutrition-focused positioning should pay close attention. As FDA continues to refine its nutrition policy initiatives—including front-of-package labeling and efforts aimed at reducing diet-related chronic disease—the Agency is signaling that health-related claims will remain an area of active review.
FDA’s Broader 2026 Food Priorities
The guidance agenda does not exist in isolation. It accompanies FDA’s broader 2026 Human Foods Program Priority Deliverables, which identify three overarching focus areas:
- Food chemical safety
- Nutrition and chronic disease prevention
- Microbiological food safety
Several initiatives under these priorities could have substantial downstream effects for regulated industry.
Food Chemical Safety
FDA continues to focus heavily on chemicals present in the food supply, including:
- Reforms to the Generally Recognized as Safe (GRAS) framework;
- Post-market review of food ingredients and additives;
- Heavy metals in foods;
- Microplastics research;
- Food-contact substances; and
- Color additives, including increased attention to natural alternatives.
Companies should expect continuing scrutiny of ingredient safety data, supplier documentation, and scientific substantiation for ingredient use.
Nutrition and Consumer Transparency
FDA’s nutrition agenda reflects a broader effort to provide consumers with more information at the point of purchase.
Examples include:
- Front-of-package nutrition labeling initiatives;
- Revisions to nutrition-related claims;
- Infant formula modernization efforts;
- Enhanced online food labeling information; and
- Continued work on dietary supplement oversight and New Dietary Ingredient (NDI) policies.
The common thread is transparency. FDA appears increasingly interested in ensuring consumers can quickly understand what is in a product and how it may affect health.
Food Safety and Traceability
FDA also continues to emphasize preventive controls, sanitation practices, contamination prevention, and supply-chain visibility.
This includes guidance supporting implementation of FSMA requirements, food traceability initiatives, and efforts to strengthen inspection and oversight programs through both federal and state resources.
What Companies Should Be Doing Now
The most important takeaway is not that any specific guidance is imminent. FDA expressly notes that agendas identify topics under consideration, and not every document will necessarily be issued or finalized within the year.
However, the agenda does provide an opportunity for companies to evaluate whether current practices align with the direction FDA appears to be heading.
Questions worth asking include:
- Are your labeling and marketing claims aligned with FDA’s current thinking, not just existing regulations?
- Do your ingredient safety files and supplier records withstand heightened scrutiny?
- Are your caffeine disclosures and nutrition communications likely to remain defensible if FDA issues additional guidance?
- Does your quality system adequately address traceability, preventive controls, and documentation expectations?
- Are regulatory, quality, marketing, and product development teams monitoring draft guidance documents before they are finalized?
Companies that evaluate these issues proactively are generally better positioned to adapt when FDA’s expectations evolve.
The Bottom Line
The 2026 Human Foods Program Guidance Agenda is not a list of new requirements. It is something arguably more useful: a roadmap of what FDA is thinking about next.
This year’s agenda highlights a clear trend toward greater transparency in food labeling, more rigorous evaluation of consumer-facing claims, continued scrutiny of ingredients and food chemicals, and increased attention to the information companies provide both regulators and consumers.
For food, beverage, and dietary supplement companies, the message is straightforward. Waiting until a guidance document is finalized—or until an FDA investigator raises an issue during an inspection—may be waiting too long.
The Guidance Agenda offers an opportunity to see where FDA is heading before the Agency gets there. Smart companies use that visibility to strengthen compliance programs, evaluate potential vulnerabilities, and prepare for the regulatory landscape that is still taking shape.
For more information on FDA’s updated guidance or for strategic counsel on FDA compliance and enforcement issues, please contact info@garg-law.com.
